Literature DB >> 29550970

Factors Influencing Clinical Follow-Up for Individuals with a Personal History of Breast and/or Ovarian Cancer and Previous Uninformative BRCA1 and BRCA2 Testing.

Sarah E Chadwell1,2, Hua He3, Sara Knapke4, Jaime Lewis5, Rebecca Sisson3, Jennifer Hopper3.   

Abstract

Genetic testing for inherited cancer risk has recently improved through the advent of multi-gene panels and the addition of deletion and duplication analysis of the BRCA genes. The primary aim of this study was to determine which factors influence the intent of individuals with a personal history of breast and/or ovarian cancer and negative or uncertain BRCA1 and BRCA2 testing to return to a hereditary cancer program for additional genetic risk assessment, counseling, and testing. Surveys were sent to 1197 individuals and 257 were returned. Of those participants who were planning to return to clinic, most cited having family members who could benefit from the test result as the primary motivation to return. Many participants who were not planning to return to clinic cited the cost of testing as a barrier to return. Cost of testing and concerns about insurance coverage were the most commonly cited barriers for the group of participants who were undecided about returning to clinic. Results from this study may be used to guide re-contact efforts by clinicians to increase patient uptake to return to clinic for up-to-date genetic risk assessment, counseling, and testing.

Entities:  

Keywords:  BRCA negative; Barriers; Breast cancer; Genetic testing; Hereditary cancer; Motivations; Multi-gene panel testing; Ovarian cancer; Return behavior

Mesh:

Year:  2018        PMID: 29550970     DOI: 10.1007/s10897-018-0241-9

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.537


  20 in total

1.  The evolution of cancer risk assessment in the era of next generation sequencing.

Authors:  Heather Fecteau; Kristen J Vogel; Kristen Hanson; Shannon Morrill-Cornelius
Journal:  J Genet Couns       Date:  2014-04-24       Impact factor: 2.537

2.  Predictors of follow-up for overweight youth and parents.

Authors:  Keeley J Pratt; David N Collier; Nicole L Walton; Suzanne Lazorick; Angela L Lamson
Journal:  Fam Syst Health       Date:  2015-01-19       Impact factor: 1.950

3.  Factors Associated with Interest in Gene-Panel Testing and Risk Communication Preferences in Women from BRCA1/2 Negative Families.

Authors:  Kristina G Flores; Laurie E Steffen; Christopher J McLouth; Belinda E Vicuña; Amanda Gammon; Wendy Kohlmann; Lucretia Vigil; Zoneddy R Dayao; Melanie E Royce; Anita Y Kinney
Journal:  J Genet Couns       Date:  2016-08-06       Impact factor: 2.537

4.  Revisiting breast cancer patients who previously tested negative for BRCA mutations using a 12-gene panel.

Authors:  Olivia Moran; Dina Nikitina; Robert Royer; Aletta Poll; Kelly Metcalfe; Steven A Narod; Mohammad R Akbari; Joanne Kotsopoulos
Journal:  Breast Cancer Res Treat       Date:  2016-10-31       Impact factor: 4.872

5.  Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer.

Authors:  M Krainer; S Silva-Arrieta; M G FitzGerald; A Shimada; C Ishioka; R Kanamaru; D J MacDonald; H Unsal; D M Finkelstein; A Bowcock; K J Isselbacher; D A Haber
Journal:  N Engl J Med       Date:  1997-05-15       Impact factor: 91.245

6.  Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel.

Authors:  Nadine Tung; Chiara Battelli; Brian Allen; Rajesh Kaldate; Satish Bhatnagar; Karla Bowles; Kirsten Timms; Judy E Garber; Christina Herold; Leif Ellisen; Jill Krejdovsky; Kim DeLeonardis; Kristin Sedgwick; Kathleen Soltis; Benjamin Roa; Richard J Wenstrup; Anne-Renee Hartman
Journal:  Cancer       Date:  2014-09-03       Impact factor: 6.860

7.  Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes.

Authors:  Laurent Castéra; Sophie Krieger; Antoine Rousselin; Angélina Legros; Jean-Jacques Baumann; Olivia Bruet; Baptiste Brault; Robin Fouillet; Nicolas Goardon; Olivier Letac; Stéphanie Baert-Desurmont; Julie Tinat; Odile Bera; Catherine Dugast; Pascaline Berthet; Florence Polycarpe; Valérie Layet; Agnes Hardouin; Thierry Frébourg; Dominique Vaur
Journal:  Eur J Hum Genet       Date:  2014-02-19       Impact factor: 4.246

8.  Barriers to cervical cancer screening in women attending the Family Medical Program in Niterói, Rio de Janeiro.

Authors:  Everton F Augusto; Maria L G Rosa; Silvia M B Cavalcanti; Ledy H S Oliveira
Journal:  Arch Gynecol Obstet       Date:  2012-08-12       Impact factor: 2.344

9.  The integration of next-generation sequencing panels in the clinical cancer genetics practice: an institutional experience.

Authors:  Caitlin B Mauer; Sara M Pirzadeh-Miller; Linda D Robinson; David M Euhus
Journal:  Genet Med       Date:  2013-10-10       Impact factor: 8.822

10.  Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing.

Authors:  Lisa R Susswein; Megan L Marshall; Rachel Nusbaum; Kristen J Vogel Postula; Scott M Weissman; Lauren Yackowski; Erica M Vaccari; Jeffrey Bissonnette; Jessica K Booker; M Laura Cremona; Federica Gibellini; Patricia D Murphy; Daniel E Pineda-Alvarez; Guido D Pollevick; Zhixiong Xu; Gabi Richard; Sherri Bale; Rachel T Klein; Kathleen S Hruska; Wendy K Chung
Journal:  Genet Med       Date:  2015-12-17       Impact factor: 8.822

View more
  4 in total

1.  Female family members lack understanding of indeterminate negative BRCA1/2 test results shared by probands.

Authors:  Deborah O Himes; Deborah K Gibbons; Wendy C Birmingham; Renea L Beckstrand; Amanda Gammon; Anita Y Kinney; Margaret F Clayton
Journal:  J Genet Couns       Date:  2019-06-14       Impact factor: 2.537

2.  Outcomes of retesting in patients with previously uninformative cancer genetics evaluations.

Authors:  Shenin A Dettwyler; Erika S Koeppe; Michelle F Jacobs; Elena M Stoffel
Journal:  Fam Cancer       Date:  2021-09-21       Impact factor: 2.446

3.  Uptake of genetic counseling and multi-gene panel testing among women in the Intermountain West with previous negative BRCA1 and BRCA2 results contacted for updated testing.

Authors:  Ryan Mooney; Whitney Espinel; Ashley Elrick; Kelsey Kehoe; Wendy Kohlmann; Kimberly A Kaphingst
Journal:  J Genet Couns       Date:  2021-09-27       Impact factor: 2.717

4.  Recontacting non-BRCA1/2 breast cancer patients for germline CHEK2 c.1100del pathogenic variant testing: uptake and patient experiences.

Authors:  Mary E Velthuizen; Rob B van der Luijt; Beja J de Vries; Marco J Koudijs; Eveline M A Bleiker; Margreet G E M Ausems
Journal:  Hered Cancer Clin Pract       Date:  2021-01-19       Impact factor: 2.857

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.